Author information
1 Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, California. Electronic address: pmills@ucsd.edu.
2 NAFLD Research Center, Department of Medicine, La Jolla, California; Université Lyon 1, Hospices Civils de Lyon, Lyon, France.
3 NAFLD Research Center, Department of Medicine, La Jolla, California; Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, California.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease in developed countries.1 Patients with nonalcoholic steatohepatitis (NASH) are considered to be at a higher risk of fibrosis progression and development to cirrhosis and hepatocellular carcinoma.